IC
CLVS

Intersect Capital’s Clovis Oncology, Inc. CLVS Stock Holding History

Intersect Capital’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-195
Closed -$16K – 391
2015
Q1 		$16K Hold
195
– – 0.01% 291
2014
Q4 		$11K Buy
+195
New +$10.2K 0.01% 338

Other funds holding CLVS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
CPCM
Clifton Park Capital Management Wilmington, Delaware $881M AUM 5.59% 1-Year Est. Return

Intersect Capital's CLVS Position: Q2 2015 in Review

Intersect Capital sold out of Clovis Oncology, Inc. (CLVS) in Q2 2015, closing a stake of 195 shares — an estimated $16K sold.

Intersect Capital first reported a position in CLVS in Q4 2014 and held it in 2 quarters. The position peaked at $16K in Q1 2015. 176 funds tracked by Wall St. Rank hold CLVS as of Q2 2015.

  • Intersect Capital reported no remaining Clovis Oncology, Inc. position as of Q2 2015 after selling out during the quarter.
  • Intersect Capital sold 195 Clovis Oncology, Inc. shares in Q2 2015, an estimated $16K.
  • Intersect Capital first reported a position in Clovis Oncology, Inc. in Q4 2014 and held it in 2 quarters.
  • Intersect Capital's Clovis Oncology, Inc. position peaked at $16K in Q1 2015.
  • 176 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2015.

Based on Intersect Capital's 13F filing for Q2 2015, filed 3 Aug 2015.